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A B S T R A C T
Background: Tuberculous lymphadenitis (TBLA) is the most common extrapulmonary manifestation of
tuberculosis (TB) in Denmark. However, the clinical features of patients with TBLA have never been
systematically studied in this setting.
Methods: Patients treated for TBLA in Central Region Denmark from 2007 to 2016 were identified using
the national TB surveillance register and The Danish Hospital Patient Registry. Data of clinical
characteristics and treatment were extracted from hospital records.
Results: Eighty-three TBLA patients were identified. The median age was 32 years (IQR 23–42); 71 (85.5%)
were migrants; 58 (69.9%) presented with cervical lymphadenopathy; and 45 (54.2%) had one or more
systemic TB symptom such as fever, chills, night sweats, fatigue, and weight loss. Sixty-five patients had
no comorbidities (78.3%). HIV co-infection was seen in five (7.2%) of the 69 who were tested for HIV.
Abscesses and/or draining sinuses were noted in 13 (15.7%) patients and 15 (18.1%) had concurrent
pulmonary infection. The median time from first hospital contact to treatment initiation was 42 days (IQR
16–82) and admitted patients were hospitalised for a median of 7 days (IQR 3–13.5). For 24 patients
(28.9%), lymph node material was not sent for mycobacterial culture and 52 (62.7%) had microbiologically
confirmed TB. Treatment outcome was successful for 70 patients (84.3%).
Conclusion: In Denmark, TBLA is mainly seen among young and previously healthy migrants presenting
with cervical lymphadenopathy and sparse systemic symptoms. The diagnosis is often considerably
delayed and not microbiologically verified, implying diagnostic difficulties. Treatment outcome needs to
be improved.
© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
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One-fourth of the world’s population is presumed to be latently
infected with Mycobacterium tuberculosis (M. tuberculosis) (Cohen
et al., 2019). The most common extrapulmonary manifestation of
tuberculosis (TB) is tuberculous lymphadenitis (TBLA) (Holden24
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infection (Fontanilla et al., 2011; Mathiasen et al., 2019a). The
diagnosis may be difficult in countries with a low incidence of TB,
as the disease is rare, which may delay appropriate treatment
(Mathiasen et al., 2019b). TBLA is often located in the cervical
lymph nodes, and many benign and malignant conditions mimic
the disease (e.g. non-specific hyperplasia, non-TB mycobacteria,
sarcoidosis, metastatic carcinomas, and malignant lymphomas),
which can be a diagnostic challenge for clinicians who are
unfamiliar with this manifestation of TB (Habermann and
Steensma, 2000). Systemic symptoms such as fever, fatigue,
weight loss, and night sweats are often sparse or absent, andciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
of tuberculous lymphadenitis in a low-incidence country, Int J Infect
nhagen from ClinicalKey.com by Elsevier on August 20, 2020.
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IJID 4423 1–6the clinical findings are usually indistinguishable from lymphade-
nitis caused by other conditions (Khan et al., 2009; Morad, 2000).
Patients with prolonged lymphadenopathy, with or without
systemic symptoms, and especially patients originating from high-
incidence TB areas should be examined for TBLA (Fontanilla et al.,
2011). Symptoms caused by perforation to surrounding organs or
compression of them may further complicate the diagnosis.
Further, in up to 23% of human immunodeficiency virus (HIV)-
negative people, treatment response may be slow and new or
enlarging lymph nodes may present following treatment initiation
(Hawkey et al., 2005; Chahed et al., 2017). This phenomenon, called
paradoxical upgrading reaction (PUR), may prompt the physician
to consider treatment failure, drug resistance, superinfection, or
other diagnoses.
Diagnosis and treatment of TBLA is based on standard TB
recommendations, but adjacent corticosteroids may be consid-
ered in patients with PUR (Fontanilla et al., 2011). Lymph node
material should be obtained by fine-needle aspiration or
preferably excisional biopsy, and should subsequently be
examined by at least microscopy, polymerase chain reaction
(PCR) and culturing. Histological examinations may support the
diagnosis together with radiological imaging, tuberculin skin
tests or interferon-gamma release assays (IGRAs) (Fontanilla
et al., 2011).
In Denmark, TBLA is seen in as many as 15.7% of TB patients
annually, most often in young migrants (Mathiasen et al., 2019a).
However, the clinical features of these patients have never been
systematically studied in this setting. Consequently, this study
aimed to evaluate the clinical features of these patients.
Materials and methods
Based on a recent nationwide analysis of TBLA in Denmark,
hospital records from all TBLA patients in the Central Region from
2007–2016 were retrieved and analysed (Mathiasen et al., 2019a).
The Central Region is one of five regions in Denmark with a
population size of approximately 1.2 million, with around
100,000–130,000 migrants, including descendants (Anon, 2020).
The demographical and socioeconomical composition of this
region is largely similar to other regions in the country.
The cohort was identified using the national TB surveillance
register and The Danish Hospital Patient Registry (DNPR)
(Schmidt et al., 2015). Patients were included if they were
notified with TBLA, including concurrent TB in other sites, to the
TB surveillance register during the study period, and/or if they
had a relevant International Diseases Classification, TenthFigure 1. Flow chart of study enrolment of tuberculous lymphadenitis patients in the 
Abbreviations: TBLAtuberculous lymphadenitis; TBtuberculosis; ICD-10International D
*ICD-10 A18.2, A18.3, A15.4, and/or A16.3.
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Danish Civil Registration Number, a unique personal identifier,
was used as observation linkage (Schmidt et al., 2014). The
diagnosis of TBLA was defined as either: 1) confirmed (culture-
positive or culture-negative but microscopy and PCR positive);
2) probable (culture-negative but microscopy or PCR positive or
pathology suggestive of TB); or 3) possible (based solely on
clinical assessment) according to the European Centre for
Disease Prevention and Control (ECDC) (2020). Treatment
outcome was defined according to the World Health Organiza-
tion (WHO) criteria (Anon, 2015). If patients were not clinically
suspected or treated for active TBLA, they were excluded.
Patients initially treated and diagnosed in one of the other four
regions were also excluded, as well as those with a relevant ICD-
10 discharge diagnosis within one year prior to the study period,
as this was considered the same episode of TB. Only patients
with M. tuberculosis complex infection were included (excluding
M. bovis BCG); patients infected with non-tuberculous mycobac-
teria were excluded.
Information from electronic hospital records was collected and
reviewed using a standardised protocol and manually examined
for all patients who were eligible for inclusion. The records contain
comprehensive data on demographic factors, symptoms and
duration of symptoms, comorbidities and risk factors, TB history,
diagnostic procedures, previous and current treatment, treatment
outcome, and complications, amongst others. The International
Reference Laboratory of Mycobacteriology at Statens Serum
Institut, Copenhagen, which serves as a diagnostic facility for
the whole country, provided culture, microscopy, PCR, drug-
susceptibility, and IGRA results for all patients who had samples
sent for examination. Additionally, supplemental regional micro-
biological, biochemical, histological, and imaging test results were
available if performed.
REDCap 7.4 was used for data storage and collection. All
statistical tests were conducted using Stata/IC 15.1 (StataCorp,
College Station, TX, USA), presented with a two-sided 95%
confidence interval and with a significance level of p < 0.05,
where appropriate. Categorial variables were compared using
Fisher’s exact test and continuous variables using Wilcoxon rank-
sum test. A modified Charlson Comorbidity Index (CCI) score was
calculated as a measure of comorbidity based on 19 conditions
classified by ICD-8/10 and the diseases were noted if present at the
first date of admission (Christensen et al., 2011). The study was
conducted in agreement with the STROBE (Strengthening the
Reporting of Observational Studies in Epidemiology) guidelines
(Chahed et al., 2017).Central Region Denmark from 2007 through 2016.
iseases Classification, Tenth Edition.
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Table 2
Diagnostic findings.
Diagnostic findings n/N (%)
ECDC case definition*
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Forty-two males and 41 females were included in the study
(Table 1). The median age was 32 years (IQR 23–42). Seventy-one
(85%) were migrants or descendants of migrants, and 22 different
countries of origin were reported, the five most frequent being:
Somalia (n = 20), Vietnam (n = 10), Philippines (n = 6), Thailand (n =
4), and Afghanistan (n = 3).
Hospital records revealed comorbidities as diabetes mellitus (n
= 5), HIV infection (n = 5), and hepatitis B/C (n = 2). No
comorbidities were registered for 65 (78.3%) patients and 68
(81.9%) had a CCI score of 0. Sixty-nine (83.1%) were HIV tested, of
which five (7.2%) were positive. A history of previous TB was noted
in eight (9.6%) and 23 (27.7%) had a presumed or confirmed TB
contact. Ethnic Danes were significantly older (median 36.5 years,
IQR 29.5–53.5) compared with migrants (median 31 years, IQR 21–
39) (p = 0.325) but did not significantly differ regarding sex, HIV,
previous history of TB, and comorbidities and CCI scores.
Symptoms and clinical findings
Swelling of a lymph node was reported in 56 patients (67.5%) on
admission, while other symptoms such as cough and chest pain
were less common (Table 1). Systemic symptoms (i.e. fever, chills,
night sweats, fatigue, and/or weight loss) were present in 45
(54.2%). The most affected lymph nodes were cervical (n = 58,
69.9%) followed by mediastinal (n = 27, 32.5%) and intraabdominal
(n = 14, 16.9%), and 60 patients had lymphadenopathy on one site
only (72.3%). Most commonly, the lymph node was present on
admission (n = 56, 67.5%) with pain or tenderness (n = 35, 62.5%).
The clinician most frequently described the lymph nodes as
unilateral, solitary and soft in consistency (Supplementary A).Table 1
Patient characteristics.
Patient characteristics n/N (%)
Females 41/83 (49.4)
Age median, years (IQR) 32 (23–42)
Age group, years
<15 7/83 (8.4)
15–24 16/83 (19.3)
25–44 43/83 (51.8)
45–64 11/83 (13.3)
>65 6/83 (7.2)
Origin of patients
Danish 12/83 (14.5)
Migrant* 71/83 (85.5)
History of TB 8/83 (9.6)
One or more concurrent disease site 23/83 (27.7)
HIV status
Positive 5/83 (6.0)
Negative 64/83 (77.1)
Unknown 14/83 (16.9)
Predisposing factors** 18/83 (21.7)
Charlson Comorbidity Index (CCI) score
0 68 (81.9)
1–2 10 (12.0)
3 5 (6.0)
Symptoms at presentation***
Fever 24/83 (28.9)
Fatigue 23/83 (27.7)
Unintended weight loss 19/83 (22.9)
Cough 16/83 (19.3)
Night sweats 13/83 (15.7)
Malaise 3/83 (3.6)
Chest pain 3/83 (3.6)
Abbreviations: IQR, interquartile range; TB, tuberculosis; HIV, human immunode-
ficiency virus.
*Migrants and descendants hereof **Alcohol or drug abuse, captivity (e.g. prison),
diabetes mellitus, haemodialysis, steroid treatment or other immunosuppressing
therapy, underweight (body mass index <18.5 kg/m2).
Please cite this article in press as: V.D. Mathiasen, et al., Clinical features 
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(15.7%).
Diagnostic features
Confirmed cases were found in 53 patients (62.7%) (Table 2).
Among patents with culture-confirmed TBLA (78.0%, n = 46/59), 20
(43.5%) and 13 (28.3%) also had a PCR (+/- microscopy) or
microscopy positive lymph node sample, respectively. M. tubercu-
losis was the aetiology in 98.1% of all culture-positive samples (n =
51/52), while one patient was infected with M. bovis. Drug-
resistant TB was found in 12.0% of the patients, including two
multidrug-resistant (MDR)-TB cases.
Lymph node material was not sent for mycobacterial culture for
24 (28.9%) of the patients and no histological examination was
performed for 15 (18.1%). For 13 (15.7%) of the patients, material
was obtained using fine-needle aspiration only, while 30 (36.1%)
had an excisional biopsy and four (4.8%) had both procedures
performed. Other methods included endobronchial ultrasound-
guided transbronchial needle aspiration (n = 7), swabs (n = 9), and/
or core biopsies (n = 8). Concurrent pulmonary infection was noted
in 15 (18.1%) and 60 (72.3%) had isolated TBLA. These findings did
not significantly differ between ethnic Danes and migrants.
Of the 27 patients diagnosed with mediastinal TBLA, five had
concomitant pulmonary TB and 13 had simultaneous involvement
of cervical lymph nodes and the remaining involvement of otherConfirmed 52/83 (62.7)
Probable 16/83 (19.3)
Possible 15/83 (18.1)
Microbiology
Culture-positive lymph node 46/59 (78.0)
Culture-positive in other site 8/47 (17.0)
PCR/microscopy positive sputum 4/44 (9.1)
Drug resistance 10/83 (12.0)
Lymph node pathology suggestive of TB** 55/68 (80.9)
Tuberculin skin test 13/15 (86.7)
IGRA positive 52/56 (92.9)
Chest radiograph at admission 65/83 (78.3)
Temperature median, C (IQR)*** 37.4 (37–38.2)
C-reactive-protein (mg/L)***
Normal (<20) 40/72 (55.6)
Moderate (20–100) 26/72 (36.1)
High (>100) 6/72 (8.3)
Erythrocyte sedimentation rate (mm/h)***
Normal (<20) 13/50 (26.0)
Elevated (>20) 37/50 (74.0)
Leukocyte count (109/L)***
Normal (3.5–9) 59/75 (78.7)
High (>9) 16/75 (21.3)
Haemoglobin (mmol/L)***
Low (<8) 40/76 (52.6)
Normal (8–10.5) 36/76 (47.4)
Albumin (g/L)***
Low (<34) 12/68 (17.7)
Normal (34–48) 56/68 (82.4)
Abbreviations: ECDC, European Centre for Disease Prevention and Control; PCR,
polymerase chain reaction; TBLA, tuberculous lymphadenitis; IGRA, interferon-
gamma-release-assay.
* The diagnosis of TBLA was defined as either 1) confirmed (culture-positive or
culture-negative but microscopy and PCR positive), 2) probable (culture-negative
but microscopy or PCR positive or pathology suggestive of TB) or 3) possible (based
solely on clinical assessment) according to ECDC (European Centre for Disease
Prevention and Control (ECDC), 2020).
** Granuloma(s), necrosis, Langerhans giant cells, PCR positive, and/or acid-fast
bacilli were considered suggestive of TB.
*** Biochemistry and temperature were not measured in all patients and was only
included when conducted within one month of first admission.
of tuberculous lymphadenitis in a low-incidence country, Int J Infect
agen from ClinicalKey.com by Elsevier on August 20, 2020.
opyright ©2020. Elsevier Inc. All rights reserved.
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
4 V.D. Mathiasen et al. / International Journal of Infectious Diseases xxx (2019) xxx–xxx
G Model
IJID 4423 1–6organs. Six were diagnosed with isolated mediastinal TB without
involvement of other lymph nodes or organs. Four of these were
based on clinical assessment, while the two others were
bacteriologically diagnosed using material collected using endo-
bronchial ultrasound-guided transbronchial needles. Among the
14 patients with intraabdominal lymph node involvement, eight
also had mediastinal gland involvement. Of the remaining six, one
had pulmonary TB. Two were diagnosed based on clinical
assessment, while three others were bacteriologically diagnosed
using material collected with fine-needle aspiration (n = 3/4). For
the last patient, it was not stated in the electronic patient record
what method was used for collecting the sample. Sixty-five (78%)
had a chest radiograph conducted within one month of admission.
Erythrocyte sedimentation rate was elevated (>20 mm/hr) in 37
(74%) of the patients.
Hospitalisation information and delays
The median duration from onset of symptoms until first
hospital contact or admission was 61 days (IQR 28–124) (n = 72).
The remaining 11 were random imaging findings (i.e. chest
radiographs and computed tomography scans taken for other
purposes). Acute admission was conducted among 17 (20.2%)
patients. The median time from first hospital contact to treatment
initiation (health care delay) was 42 days (IQR 16–82) (n = 83) and
patients were most often seen in one or two departments prior to
the one initiating treatment. Patients attended a median of 13 (IQR
9–17) outpatient clinics, excluding patients with relapse or drug-
resistant TB and admitted patients were hospitalised for 1–50 days
(median 7, IQR 3–13.5). Health care delay did not significantly
differ when comparing Danes and migrants.
Treatment and treatment outcome
Fifty-six patients (67.5%) were treated for six months with a
standard TB four-drug regimen, while 18 (21.7%) had their
treatment prolonged by the clinician, eight (9.6%) stopped
medication, and one patient died during treatment due to TB
meningitis. Five (6%) of the patients received adjacentFigure 2. Treatment outcome defined according to the Wo
Please cite this article in press as: V.D. Mathiasen, et al., Clinical features 
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(84.3%), with completed noted for 67 (80.7%) and cured for three
(3.6%) (Figure 2). One of these ‘cured’ patients had concomitant
pulmonary TB and was culture-negative in the last month of
treatment and on at least one previous occasion. The remaining
two did not have concomitant pulmonary TB and should have been
classified as completed. Six patients defaulted (7.2%), while the
remaining eight (12.0%) were noted as failure (n = 2), transferred (n
= 3), dead (n = 1), or unknown (n = 1). The two cases of treatment
failure were due to MDR-TB. Symptoms consistent with PUR
(defined as draining sinuses, enlarging or newly involved lymph
nodes) were reported in eight (9.6%) patients within 10 days of
treatment initiation. Six of these eight were females, with a median
age of 34 years (IQR 32–37), of which five were migrants. Ethnic
Danes and migrants did not significantly differ regarding
treatment outcome (p = 0.362).
Discussion
Patients with TBLA in Denmark were mainly young and
previously healthy migrants with affection of the cervical lymph
nodes. Systemic symptoms were rarely present. Approximately
60% of the patients were culture-confirmed, while almost one-
third did not have material sent for mycobacterial culture. Further,
a considerable health care delay was identified, confirming the
challenges of diagnosing TBLA. Finally, the treatment success rate
was 84.3%. PUR was rare and mainly seen among young migrant
females. In accordance with a previous study, the majority of
patients were young migrants with the majority being of Somalian
origin (Mathiasen et al., 2019a), most likely reflecting the
substantial migration from Somalia to Denmark and the enormous
burden of TB seen in this population group (Lillebaek et al., 2002).
Physicians should be aware of the higher a priori risk of TB, HIV and
other communicable diseases in migrants such as refugees and
asylum seekers (Alberer et al., 2018; Deen et al., 2018). As
previously discussed (Mathiasen et al., 2019a), many of the TBLA
cases have unique MIRU-VNTR genotypes and are likely to be
reactivation of previously acquired infection, as most TB among
migrants in Denmark is estimated to be imported infectionrld Health Organization (WHO) criteria (Anon, 2015).
of tuberculous lymphadenitis in a low-incidence country, Int J Infect
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IJID 4423 1–6(Lillebaek et al., 2001). Furthermore, as previously observed, a
majority of females was not found (Mathiasen et al., 2019a),
although gender differences are often highlighted in the literature
(Fader et al., 2010; Purohit et al., 2009). TBLA is the most common
presentation of extrapulmonary TB (EPTB) in Denmark (Hatleberg
et al., 2014; Leutscher et al., 2012; Kristensen et al., 2020; Zhang
et al., 2011) and it has previously been reported in up to as many as
three-fourths of EPTB cases in the study region, (Leutscher et al.,
2012). As discussed by Behr and Waters, an alternative theory is
that TB can be viewed as a lymphatic disease with a pulmonary
portal of entry, rather than a pulmonary disease, explaining the
distinctive involvement of the lymphatic system (Behr and Waters,
2014). Unfortunately, this retrospective study could not prove this
theory; thus, it must remain a speculative explanation.
Few patients had comorbidities described in the hospital
records, in agreement with notifications from the TB surveillance
register (Mathiasen et al., 2019a). However, it was observed that as
many as 83.1% were HIV tested compared with the 8% seen in the
nationwide study, indicating that notification of HIV could be
improved (Mathiasen et al., 2019a). Consistent with the low
prevalence of HIV co-infection in Denmark, 7.2% were HIV/TB co-
infected (Dragsted et al., 1999). Consequently, few HIV infected
people are vulnerable to TB and few are exposed. EPTB is a frequent
finding in migrants without any signs of immunosuppression,
perhaps as a consequence of late presentation TB. Most migrants
are infected prior to arrival in Denmark but reactivate M.
tuberculosis infection after arrival (Lillebaek et al., 2001). None-
theless, in almost 20% of the patients, HIV testing was not
conducted and it must be emphasized that HIV be ruled out in all
patients with TB, due to the close association between these
conditions (Shafer et al., 1991).
Comparable with the literature, most patients had unilateral
cervical lymphadenopathy, 20% complained of coughing and 54%
had one or more systemic symptoms (Fontanilla et al., 2011). The
involved lymph node was often affected at admission and most
patients had isolated TBLA (72.3%). In a recent nationwide study, it
was estimated that almost 90% of TBLA cases presented without
concomitant TB in other sites (Mathiasen et al., 2019a), which in
the light of these data might be an overestimation due to
incomplete notification. Consequently, more may be contagious
or have disease at other sites than previously assumed. Three-
quarters of the patients had affected cervical nodes, which was
similar to many other studies (Fontanilla et al., 2011), highlighting
that patients presenting with chronic lymphadenopathy of the
neck should be considered for TBLA, especially migrants from high-
incidence TB settings. Abscesses and sinuses were seen in up to
16%, which is evidence of a substantial morbidity in these patients.
Culture verification of EPTB has generally been low, due to
difficulties in sample collection and the paucibacillary nature of M.
tuberculosis. Diagnosis was possible in 18% of patients (i.e. solely
based on clinical suspicion), while the diagnosis was confirmed in
62.7%. This points out how important it is to carefully collect
material, preferably by excisional biopsy, and send it for
mycobacterial culture examination (Lau et al., 1990). The gold
standard for diagnosing TB remains based on culturing and 43.5%
and 28.3% of the culture-confirmed lymph node cases also had a
PCR and microscopy positive sample, respectively, establishing the
importance of collecting material for culture. Furthermore, routine
mycobacterial examination enables physicians to rule-out drug
resistance and non-TB mycobacteria (Adzic-Vukicevic et al., 2018).
Yet, a considerable number of patients did not have lymph node
material sent for mycobacterial culture or histological examina-
tion, and it is assumed that the diagnosis of TB is often not
considered before late into the course of disease.
Diagnosing TBLA may be challenging, as it involves monitoring
the treatment response, PUR may puzzle the clinician, isolatesPlease cite this article in press as: V.D. Mathiasen, et al., Clinical features 
Dis (2020), https://doi.org/10.1016/j.ijid.2020.07.011Downloaded for Anonymous User (n/a) at BS - University of Copenh
For personal use only. No other uses without permission. Cmight be drug-resistant (12%) and lymph nodes biopsies, in
comparison with sputum, are not routinely collected at follow-up.
Blood sampling may aid the clinician and biomarkers such as C-
reactive-protein, erythrocyte sedimentation rate, leukocytes,
haemoglobin, and albumin may be useful. An elevated erythrocyte
sedimentation rate was seen in 74% of the current cohort. Clinical
parameters such as weight gain, improvement of symptoms, and
regression of clinical signs may be particularly useful in assessing
treatment success in EPTB patients (Jørstad et al., 2019).
As mentioned, it is assumed that the diagnosis of TBLA in
Denmark is often delayed and not considered before late into the
course of disease. The disease is rare, and a high index of suspicion
is required (Mathiasen et al., 2019a; Mathiasen et al., 2019b). This is
also supported by the substantial health care delay of a median of
42 days (IQR 16–82), which is comparable to a recent systematic
review (Mathiasen et al., 2019b). It is important that all patients
with TBLA are screened for pulmonary symptoms and examined
with chest radiographs to preclude contagious TB. Twenty-two
percent of patients did not have chest radiographs taken within
one month of the first admission, potentially delaying the
diagnosis of pulmonary TB, but also prolonging the period of
contagiousness.
Treatment outcome was successful in 84.3% of patients, which
is lower than the overall treatment outcome of extrapulmonary
(90.9%) and pulmonary TB (84.1%) in recent reports from 2014
underlying the difficulties in managing this manifestation of TB
(Holden et al., 2019a; Holden et al., 2019b). However, the report on
EPTB did not include patients with concomitant pulmonary TB.
The main limitation of the study was the retrospective design,
as collection of data relied on the individual physicians’ completion
of hospital records. Consequently, information on lymph node
characteristics, TB risk factors, risk of exposure, and comorbidities,
among others, was not necessarily presented in the records. In
addition, biochemical, microbiological and histological examina-
tions were not systematically performed in all patients. This also
demonstrates that the current management of TBLA patients in
Denmark is suboptimal (e.g. the incomplete testing for M.
tuberculosis and HIV). Another limitation was the small number
of patients included in the study.
In conclusion, TBLA patients usually present with cervical
lymphadenopathy, the diagnosis is often substantially delayed, and
half of the patients have systemic symptoms, which is similar to
observations in other studies. It is of importance that material is
sent for microbiological examination to establish a diagnosis
without delay, discover drug resistance and initiate sufficient
treatment. This study suggests that TBLA may be a challenging
diagnosis and that the clinical management could be improved in
this setting.
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